The authors performed meta-analyses to study the prognostic significance of CD44 in gliomas, and drew the conclusion that high expression of CD44 may predict poor survival in glioma, particularly in WHO grade II–III gliomas. This evidence concerns the gene CD44 and central nervous system cancer.